Long-Term Proton Pump Inhibitor Use is a Risk Factor for Mortality in Patients Hospitalized for COVID-19.

Yozgat, Ahmet; Kasapoğlu, Benan; Can, Güray; Tanoğlu, Alpaslan; Sakin, Yusuf Serdar; Yalçin, Kadir Serkan; Gürler, Müjgan; Kaplan, Mustafa; Kaban, Mehmet Göktürk; Kirsoy, Mehmet; Kara, Umut; Kekilli, Murat

AIM The aim of this study is to evaluate whether the long-term (?4 weeks) use of proton pump inhibitors (PPIs) is a risk factor for intubation requirement and mortality in patients hospitalized for COVID-19. METHODS In this multicentric retrospective study, a total of 382 adult patients (?18 years of age) with confirmed COVID?19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periods during which they used PPIs: the first group included patients who were not on PPI treatment, and the second group included those who have used PPIs for more than 4 weeks. RESULTS The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did not use any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR: 1.047, 95% CI: 1.026?1.068), current smoking (HR: 2.590, 95% CI: 1.334?5.025), and PPI therapy for more than 4 weeks (HR: 1.83, 95% CI: 1.06?2.41) were found to be independent risk factors for mortality. DISCUSSION The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes for patients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19 treatment.